Maze Therapeutics Ratios (2024-2026) | MAZE

Ratios Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
Gross Margin (Quarter) 91.04%
EBT Margin (Quarter) 938.55%-1,001.24%19.58%-97.98%
EBIT Margin (Quarter) 930.37%-969.16%19.49%-132.77%
EBITDA Margin (Quarter) 930.37%-969.16%19.49%-132.77%
Operating Margin (Quarter) 930.37%-969.16%19.49%-132.77%
Net Margin (Quarter) 927.04%-989.24%25.98%-97.98%
FCF Margin (Quarter) 968.63%-935.24%15.34%-196.03%
Efficiency
Assets Average (Quarter) 286.69M318.18M362.79M409.59M408.42M
Invested Capital (Quarter) 40.00M
Asset Utilization Ratio (Quarter) -0.47-0.47-0.420.05
Leverage & Solvency
Interest Coverage Ratio (Quarter) -0.34-0.347.09
Debt Ratio (Quarter) 0.09
Times Interest Earned (Quarter) -0.34-0.347.09
Valuation
Enterprise Value (Quarter) -30.02M-175.06M-149.61M-196.81M-294.37M-264.54M-383.94M-341.92M-352.38M
Return Ratios
Return on Sales (Quarter) 0.09%-0.10%0.00%0.00%0.01%0.01%-0.01%
Return on Capital Employed (Quarter) 18.73%-42.19%-39.50%-36.92%-34.62%
Return on Assets (Quarter) 0.00%0.00%0.00%0.00%0.00%